License agreement content: What should a license agreement actually cover?

Key Takeaways

• A license agreement is a contract that grants defined rights to use an asset, usually without transferring ownership of that asset.

• The content of a license agreement depends heavily on what is being licensed, whether that is a patent, software, know-how, data or a broader technology package.

• Timing matters. A university spin-out license, an R&D-stage biotech partnering deal and a commercial-stage product license raise very different drafting issues.

• The core clauses of a license agreement usually include the licensed subject matter, scope, exclusivity, option rights, sublicensing, financial terms, performance obligations, liability, IP control and termination

What is a license agreement in the first place?

A license agreement is a contract by which one party grants another party defined rights to use something. In an IP context, that “something” is often a patent, software, know-how, data, a trademark or a combination of several of these elements. The key point is that the agreement defines what may be used, by whom, for what purpose, in which territory, for how long and on what financial terms.

That makes a license different from a full transfer of ownership. The right holder does not sell the asset outright, but allows another party to use it within agreed limits. That is why licensing is so common in life sciences. It allows companies to develop, manufacture or commercialize technology without giving up the entire asset.

A useful way to think about it is this: a license is a contract that grants permission to use rights, usually rights in intangible assets. It is therefore comparable in broad terms to a lease agreement for a physical physical object or property, such as equipment, office space or laboratory facilities, but the underlying asset is different. That difference drives different questions on structure, risk and commercial terms.

What does a license agreement regulate?

A license agreement regulates which rights are granted and on which terms. In practice, that means it defines not only whether another party may use an asset, but also how far that permission goes, what the economic deal looks like and who carries which risks. This is why a license agreement is rarely just a simple permission statement. It is the legal framework that turns a commercial understanding into a workable allocation of rights, restrictions and responsibilities.

That is also why the next question matters most in practice: what should this framework actually contain?

What content does a license agreement typically include?

A license agreement typically includes a core set of clauses that translates the commercial deal into legal text. The exact drafting differs from case to case, but the following building blocks appear in most serious licensing arrangements:

• Licensed subject matter: The agreement must define what is actually being licensed. That may include patents, patent applications, software, source code access rights, know-how, data, biological materials, trademarks, regulatory documentation or a combined package. 

• Scope of the license: This clause defines what the licensee may do. It often covers field of use, territory, duration and whether the rights extend to research, development, manufacturing, regulatory use, marketing or commercialization. 

• Exclusivity: The agreement should clarify whether the license is exclusive, sole or non-exclusive. This is often one of the most heavily negotiated commercial issues. 

• Sublicensing: If the licensee may grant sublicenses, the agreement should say under what conditions. This is especially important in biotech and pharma, where external development, manufacturing and distribution are common. 

• Option rights: In some deals, a party does not receive a full license immediately, but only an option to obtain one later. That can be useful where technology is still under evaluation or where key data is not yet available. At the same time, an option can encumber the IP because it limits the licensor’s freedom to offer the same rights elsewhere during the option period or subject to the option terms. 

• Financial terms: The economics may include upfront payments, option fees, milestone payments, royalties, minimum payments or cost-sharing mechanisms. The right structure depends strongly on timing and development stage. 

• Performance obligations: Many licensors do not want the asset to remain unused. Development milestones, diligence obligations and commercialization commitments are often central parts of the bargain. 

• Technology transfer and support: A bare license is often not enough. The licensee may also need know-how transfer, software implementation support, manufacturing documents, assay protocols, training, access to materials or regulatory assistance. 

• IP maintenance and enforcement: The contract should allocate responsibility for prosecution, maintenance, defense and enforcement of IP rights. 

• Improvements and new developments: The agreement should address what happens if the licensee improves the technology or generates follow-on IP. 

• Liability and indemnities: This is where risk allocation becomes real. The agreement should address warranties, liability caps, excluded damages and third-party claim handling, including who controls the defense and who bears the cost. 

• Term, termination and post-termination effects: The agreement should regulate what happens if the deal ends, the licensee underperforms or the relationship otherwise breaks down. 

A short example shows how dense even a basic patent-focused license grant can become in practice:

Subject to the provisions of this Agreement, Licensor hereby grants to Licensee an exclusive (even as to Licensor), milestone- and royalty-bearing, non-transferable, non-sublicenseable license under the Licensed Technology to research, develop, make, use, sell, offer to sell, import or otherwise Commercialize Licensed Product in the Field in the Territory.

Even this short extract already contains many of the key deal points: exclusivity, payment logic, transfer restrictions, sublicensing limits, the licensed acts and the scope of field and territory.

For readers who want a deeper clause-by-clause review, our existing article “License agreement checklist: the 10 sections you need to review on every deal” is a useful next step.

How does the licensed asset change the agreement?

The licensed asset changes the agreement fundamentally because different assets create different legal and commercial risks. This is one of the main reasons why licensing is rarely a copy-paste exercise.

A patent license is often built around patent family definition, territorial scope, infringement risk, exclusivity, prosecution control and enforcement rights. In an R&D-stage biotech or pharma deal, that usually ties directly into development milestones, regulatory strategy and field-of-use boundaries. The wording often reflects that broader commercial ambition. A patent license grant in a drug-development setting may therefore cover rights to research, develop, make, use, sell, offer to sell, import and otherwise commercialize the licensed product, all within a tightly defined field and territory.

A software license often looks different. The central questions may include user scope, deployment model, hosting structure, updates, maintenance, interoperability, source code access, cybersecurity, data rights and regulatory compliance. In life sciences, software may also sit inside a regulated product or a clinical or operational workflow, which means a standard software template often misses the real risk points.

The contrast becomes clearer when one looks at actual wording. A software evaluation license may read as follows:

1.1 In consideration of the Fee paid by the Customer to Service Provider, Service Provider hereby grants to the Customer a revocable, non-exclusive, non-transferable right, without the right to grant sub-licences, to use (i) the Subscription Services and the Documentation and (ii) the Customer-Hosted Software during the Licence Term solely for the Customer's evaluation of the potential to further its internal research and development programmes and not for any other purpose.1.2 For the purposes of clause 1.1, the Customer’s use of the Software shall be restricted to use by Authorised Users only and shall (i) be limited to the Maximum Data Set Size and (ii) in relation to the use of the Customer-Hosted Software, be in object code form only.1.3 The Customer may not use the Software other than as specified in clauses 1.1 and 1.2 without the prior written consent of Service Provider, and the Customer acknowledges that additional fees may be payable on any change of use or increase in use approved by the Service Provider.

This is a very different licensing logic from a patent partnering deal aimed at broad product development and commercialization. The clause is narrower, more use-case specific and much more focused on user restrictions, technical access and internal evaluation limits.

A know-how license is different again because know-how is harder to define, easier to misuse and often impossible to separate cleanly from confidentiality and technology transfer. This is particularly relevant in biotech and pharma, where the real value may sit in tacit manufacturing knowledge, formulations, assay conditions, SOPs, analytical methods, process parameters or regulatory experience. In those cases, confidentiality, training, documentation, use restrictions, audit rights and proof of transfer often matter as much as the headline license grant. If the know-how has a regulatory dimension, for example because it relates to validation methods, CMC processes, dossier strategy or product release systems, the agreement may also need to address support obligations, data handover and ongoing cooperation in a much more operational way.

In many life sciences deals, the most realistic structure is a mixed package license. A university spin-out may receive patent rights together with background know-how and access to research materials. A biotech partnering deal may combine patents, data, regulatory support and manufacturing know-how. A commercial product license may also pull in trademarks, supply arrangements, quality responsibilities and market-facing obligations. Once the licensed package is understood this way, it becomes much easier to see why the content of the agreement must change with the asset.

Why does timing matter so much in license agreements?

Timing matters because the same technology can require a very different agreement depending on where the product or business stands. The stage of the asset changes the economic logic and therefore the contract.

One important reason is that licensing does not always start with an immediate license grant. In many life sciences deals, the parties first agree on an option. An option gives one party the contractual right, but not the obligation, to take a license later if certain conditions are met. Those conditions may be linked to technical validation, due diligence, clinical data, internal approval or some other trigger. At first sight, this can look modest. The final license has not yet been granted, so lay readers often assume the licensor remains largely free. In practice, that can be wrong.

An option can be a very significant commercial constraint on the asset. If the option holder can exercise the option unilaterally during the option period, the licensor is often commercially blocked on that asset for that time. The licensor may no longer be able to offer the same rights freely to another party, may have to structure other discussions around the outstanding option, and may lose negotiating leverage because interested third parties know that the asset is already committed elsewhere. In that sense, the key business effect often begins before the actual license is signed.

A typical option mechanism may therefore look deceptively simple in wording, while being commercially very powerful in effect. For example, a clause may grant an “exclusive option during the Option Period” to obtain a later assignment or license, allow exercise by written notice and payment of an option exercise fee, and provide for automatic expiry if the option is not exercised in time. The legal drafting may look procedural. The commercial effect can be much bigger: during the option period, the asset may no longer be fully available for alternative transactions.

This is especially important because timing changes the role that options and licenses play.

In a university spin-out, the focus is often on getting the technology into the new company in a way that remains investable. The agreement may need to address background IP, publication rights, academic research carve-outs, founder involvement, improvement rights and future financing sensitivity. Option structures can appear here where the spin-out first secures a right to take a broader license later, for example once funding is in place or certain development steps are completed. That can help sequence the transaction, but it also means the underlying IP may already be committed in a way that affects later investors and alternative strategic paths.

In an R&D-stage biotech partnering deal, the role of an option is often even more commercially sensitive. A pharma company may want to reserve the right to take a license after seeing preclinical, translational or clinical data. From the biotech’s perspective, that can be attractive because it brings early interest, funding or validation. But the price is often reduced freedom during the option period. If the pharma counterparty can decide unilaterally whether to exercise, the biotech may be effectively blocked from giving the same opportunity to another partner while the option remains open. That is why option rights are often not just a preliminary topic. They can be one of the most value-determining parts of the deal.

Only after that option stage, or sometimes without an option stage at all, do parties move into the full license structure. At that point, the issues shift depending on timing.

In a commercial-stage license for a marketed product, the agreement often becomes more operational. The deal may need to address trademarks, supply, quality, pharmacovigilance interfaces, market access, pricing mechanics, inventory, regulatory maintenance and ongoing commercial reporting. Here, the main challenge is often less scientific uncertainty and more operational coordination.

Timing also affects diligence obligations. In a late-stage or commercial setting, the licensor often expects the licensee not merely to hold rights, but to use them actively. That is why one often sees clauses requiring “Commercially Reasonable Efforts” to commercialize the licensed product, launch as early as possible after marketing authorization, dedicate specified resources and work toward agreed sales targets. In other words, the agreement stops being only a contract about access to IP and becomes a contract about actual market execution.

This is exactly why license agreement content cannot be discussed as though every deal lived at the same stage. A spin-out license, an option-based partnering deal and a post-launch commercialization license may all be called license agreements, but they solve different problems. And in some cases, the real commercial turning point is not the final license at all, but the option that comes before it.